Clinical Neuropsychologist Online
  • Clinical Neuropsychologist
    • Neuropsychological Assessment
      • What is Clinical Neuropsychology?
      • Our Clinical Neuropsychology Consults
      • Post-COVID Neuropsychological Assessment
      • Neuropsychological Rehabilitation Online & in Hong Kong
    • Our Clinical Neuropsychologist
      • Clinical Neuropsychologist Referral
      • Clinical Neuropsychology Intake Upload
    • Clinical Neuropsychologist Online Appointments
      • Intake Appointment
      • Neuropsychologist Consult
      • Neuropsychology Feedback Session
  • Neuropsychology Knowledgebase
    • Acquired Brain Injury
    • Alzheimer’s Disease Neuropsychology
    • Dementia Neuropsychology
    • Memory Neuropsychology
    • Neuroanatomy & Neuroradiology
    • Neuropsychological Assessment
    • Neuropsychological Disorders
    • Neuropsychological Rehabilitation
    • Traumatic Brain Injury
  • Neuropsychology CPD
    • Latest Journal Articles
    • Cognitive Neuropsychology
    • Dementia
    • Neuro Podcasts
    • Neuroimaging
    • Neuropsychology (general)
    • Neurorehabilitation
    • Neuroscience
    • Paediatric Neuropsychology
  • Neuropsychology Courses
  • Newsletter
  • Brain Lounge
Select Page

Plasma β‐synuclein associates with hippocampal synaptic density measured with [11C]UCB‐J PET and plasma tau markers in Alzheimer’s disease

by Clinical Neuropsychologist Online | Wednesday, October 28, 2026 | Dementia

Abstract INTRODUCTION Plasma β-synuclein is a promising blood-based synaptic biomarker, but relationships with synaptic density as indicated by [11C]UCB-J positron emission tomography (PET), and blood biomarkers of Alzheimer’s disease (AD) pathology,...

Cost‐effectiveness of lecanemab for early Alzheimer’s disease in China

by Clinical Neuropsychologist Online | Wednesday, October 28, 2026 | Dementia

Abstract BACKGROUND Although lecanemab has demonstrated clinical efficacy in early Alzheimer’s disease (AD), its cost-effectiveness in China remains uncertain. This study evaluated the long-term cost-effectiveness of lecanemab in Chinese patients from a societal...

Social cognition alterations in neurocognitive disorders

by Clinical Neuropsychologist Online | Tuesday, October 27, 2026 | Neuropsychology (general)

Journal of Neuropsychology, EarlyView. If you do not see content above, kindly GO TO SOURCE. Not all publishers encode content in a way that enables republishing at Neuro.vip. This post is Copyright: | October 27, 2026 Neuro-General Previous...

Response inhibition in children and adolescents with fragile X syndrome

by Clinical Neuropsychologist Online | Tuesday, October 27, 2026 | Paediatric Neuropsychology

. If you do not see content above, kindly GO TO SOURCE. Not all publishers encode content in a way that enables republishing at Neuro.vip. This post is Copyright: | October 27, 2026 Neuro-Paediatric Previous Page

Pathway‐specific polygenic risk scores modify the association between amyloid and tau PET accumulation in patients with Alzheimer’s disease

by Clinical Neuropsychologist Online | Tuesday, October 27, 2026 | Dementia

Abstract BACKGROUND Genome-wide association studies (GWASs) identified multiple genetic variants associated with Alzheimer’s disease (AD) risk, yet the biological pathways linking these to amyloid and tau pathology remain unclear. METHODS We conducted a...
« Older Entries
Next Entries »

Posts by Category

  • Cognitive Neuropsychology
  • Dementia
  • Neuro Podcasts
  • Neuroimaging
  • Neuropsychology (general)
  • Neurorehabilitation
  • Neuroscience
  • Paediatric Neuropsychology

Neuropsychology Newsletter &
Interest List

S U B S C R I B E

© PsyAsia Neuropsychology. Clinical Neuropsychologist Hong Kong & Online. Part of the Psychology1 Group. All Rights Reserved.
DISCLAIMER: We are not responsible for any inaccuracies at this site. No medical advice is being offered to you personally.
No medical contract is formed by you visiting PsyAsia Neuropsychology. 🕉️🔱☸️